HeyJaredBhanvi Satija
- Indexed articles, last 90 days
- 3
- Latest publication
- Sep 8, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 20, 2026
Latest articles
Novartis twin drug setbacks pile pressure on pipeline and CEO (opens the original)
Read excerpt
By Bhanvi Satija, Dave Graham and Marleen Kaesebier ZURICH, Sept 8 (Reuters) - Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major trial setback in days and sending the Swiss drugmaker's shares down about 9% in one of its worst trading days on record. The setback for del-desiran, which Novartis acquired through its recent $12 billion acquisition of Avidity, increases pressure on CEO Vas Narasimhan and his M&A strategy to buil
Sanofi raises sales outlook on Dupixent strength in boost for new CEO (opens the original)
Read excerpt
LONDON, July 30 (Reuters) - Sanofi on Thursday raised its full-year sales forecast on the back of strong demand for blockbuster asthma drug Dupixent, with investors focused on new CEO Belen Garijo's first address for her plans to revive the French company's drug development engine. Garijo has taken the helm at a time when the drugmaker is under investor scrutiny to secure a growth plan beyond the company's star drug Dupixent. In her first weeks on the job, Garijo has overhauled her executi
Novartis faces drug pipeline test with valuation premium in focus (opens the original)
Read excerpt
LONDON, July 20 (Reuters) - Novartis investors will look beyond Tuesday's quarterly results for indications about three major drug trial readouts due in the second half of the year seen as vital to justifying the Swiss drugmaker's premium valuation. Analysts say the experimental drugs - pelacarsen for cardiovascular disease, remibrutinib for multiple sclerosis and genetic disorder drug del-desiran - could shape the Basel-headquartered firm's growth outlook into the next decade, as looming pate
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.